论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
Authors Hanna AF, Abraham B, Hanna A, Smith AJ
Received 25 March 2017
Accepted for publication 11 May 2017
Published 18 August 2017 Volume 2017:10 Pages 305—308
DOI https://doi.org/10.2147/IMCRJ.S137975
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Amy Norman
Peer reviewer comments 2
Editor who approved publication: Dr Ronald Prineas
Abstract: Post-treatment Lyme disease syndrome (PTLDS) is a pain disorder
for which there remains no gold standard treatment option. Here, we report a
case of PTLDS in a female patient whose pain was refractory to treatment
options such as radiofrequency ablation, vitamin infusion therapy, opioid
analgesics, and other pharmacotherapies. The patient commenced an experimental
intravenous ketamine infusion therapy at the Florida Spine Institute
(Clearwater, FL, USA) and achieved relief from her chronic pain, an improved
quality of life, reduced depression and suicidal ideation, and reduced opioid
consumption.
Keywords: chronic Lyme,
late Lyme, pain, analgesic, suicidality, depression
摘要视频链接:Ketamine for post-treatment
Lyme disease